Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FSU95
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,424
Award facts
- Contract value 100% obligated
- $3,424.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml autoinjector units. This firm fixed-price delivery order, awarded on November 3, 2025, with an ultimate completion date of November 25, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's medical supply chain, supporting military healthcare facilities globally through the PPV-G GEN V program. The broader $30.3 billion acquisition strategy authorizes the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables. As a small business prime vendor, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity with multiple awards across diverse therapeutic categories, positioning it as a key regional supplier for the military medical system's recurring pharmaceutical requirements.
Quick answers
Who was awarded contract SPE2DB26FSU95?
SPE2DB26FSU95 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DB26FSU95 worth?
The government has obligated $3,424 on SPE2DB26FSU95.
Is contract SPE2DB26FSU95 an order under another contract?
Yes. SPE2DB26FSU95 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB26FSU95 competed?
The extent of competition for SPE2DB26FSU95 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award